West Pharma Beats Q2 Estimates, Raises Full-Year Sales and EPS Guidance
WST sits 80% above its 52-week low of $211.1.
Summary
West Pharmaceutical reported Q2 2026 results above expectations, with net sales up 13.8% and adjusted EPS up 28.8%. Full-year guidance was raised for both sales and EPS, reflecting strong biologics and GLP-1 demand.
Key Events · Earnings and Guidance · WST
-
Q2 Earnings Beat
Net sales of $872.3M grew 13.8% reported (12.7% organic), and adjusted-diluted EPS of $2.37 rose 28.8% YoY, exceeding expectations.
-
Full-Year Guidance Raised
2026 net sales guidance increased to $3.345B-$3.380B (from $3.295B-$3.350B), and adjusted-diluted EPS guidance raised to $8.85-$9.05 (from $8.40-$8.75).
-
Q3 Guidance Introduced
Q3 2026 net sales expected at $820M-$835M (1.9%-3.8% reported growth) and adjusted-diluted EPS of $2.14-$2.24.
-
Share Repurchases
Repurchased 1.8M shares for $454.3M in H1 2026 at an average price of $258.03 per share under the $1B buyback program.
Analysis · WST · Industrial Applications And Services
A strong second quarter saw net sales reach $872.3 million, up 13.8% reported and 12.7% organic, fueled by biologics and GLP-1 demand. Adjusted EPS of $2.37 surged 28.8% year-over-year, exceeding expectations. Management raised full-year 2026 guidance for both net sales and adjusted EPS, signaling confidence in sustained momentum. The company also repurchased 1.8 million shares for $454.3 million in the first half, returning capital to shareholders. This earnings beat and guidance raise, coming after a recent cybersecurity incident and CEO transition, reinforces the company's operational resilience and growth trajectory.
At the time of this filing, WST was trading at $380.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $25.3B. The 52-week trading range was $211.10 to $367.66. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.